Tamoxifen and the Endometrium: Monitoring During Breast Cancer Hormone Therapy

Hormone receptor-positive breast cancer is treated with endocrine therapy for five to ten years after surgery. For premenopausal women in particular, selective estrogen receptor modulators (SERMs) are a mainstay — and tamoxifen is the representative drug. Tamoxifen blocks estrogen receptors in breast tissue, which is why it prevents recurrence, but it has a weak estrogen-like effect on the endometrium, the lining of the womb, where long-term use is associated with endometrial polyps, hyperplasia, endometrial carcinoma and, rarely, uterine sarcoma. The 2021 Chinese expert consensus sets out how to manage that risk: not by avoiding an effective cancer treatment, but by structured gynaecological monitoring alongside it.

Who is at higher risk

Risk rises with longer duration of treatment, higher cumulative dose, older age and postmenopausal status, a higher body mass index, a history of endometrial hyperplasia or polyps, pre-existing uterine fibroids or adenomyosis, diabetes or hypertension, and combined hormone therapy. Tamoxifen use after menopause carries more endometrial risk than use before it. The absolute risk of endometrial cancer is small but real and is higher than in women not taking the drug — and the consensus makes clear that this does not change the recommendation to take endocrine therapy, because the reduction in breast cancer recurrence and mortality is substantially larger.

Before starting and during treatment

Before SERM therapy begins, higher-risk patients should have a gynaecological assessment: transvaginal ultrasound, with contrast-enhanced ultrasound or pelvic MRI where available, and hysteroscopy with curettage if the endometrium looks abnormal. During treatment, monitoring is stratified by risk — a baseline examination, then periodic ultrasound, typically at intervals of six to twelve months for higher-risk patients and less frequently for lower-risk ones, with additional testing if symptoms appear. The most important trigger is symptoms: any abnormal uterine bleeding or any bleeding after menopause in a woman on a SERM should prompt gynaecological review promptly rather than waiting for the next scheduled scan.

What the scan looks for and what happens next

The endometrial thickness measured by ultrasound is the usual screening measure, interpreted in the context of menopausal status and symptoms; a thickened, irregular or vascular endometrium, or one containing a polyp, leads to hysteroscopy with directed biopsy. Findings are managed by their pathology: polyps are removed, hyperplasia without atypia is usually managed with progestin treatment or observation with follow-up sampling, atypical hyperplasia — a precancerous lesion — is treated more definitively, and carcinoma is staged and treated according to standard gynaecological oncology principles, which usually means surgery.

Coordination of care

The consensus's central practical recommendation is that a gynaecologist should be involved in follow-up of women on SERM therapy rather than the oncology team alone — obstetrics and gynaecology input improves detection and risk control. Practical advice for patients: report bleeding, discharge or pelvic pain promptly; keep every gynaecology appointment even if you feel well, because endometrial change is usually silent; and never stop endocrine therapy on your own because of a gynaecological finding — the two problems are managed together, and stopping breast cancer treatment carries the greater risk.

Questions to ask

Am I at higher or standard risk for endometrial problems? How often should I have a scan, and will a gynaecologist be involved? What symptom should make me call? If an abnormality is found, is my endocrine therapy changed or continued? And — importantly — what symptom would suggest something gynaecological rather than a side effect I should tolerate?